Novonix (NVX) Current Deferred Revenue (2020 - 2025)

Novonix (NVX) has 6 years of Current Deferred Revenue data on file, last reported at $146475.0 in Q4 2025.

• For the quarter ending Q4 2025, Current Deferred Revenue rose 16.2% year-over-year to $146475.0; the trailing twelve-month figure through Dec 2025 stood at $146475.0 (up 16.2% YoY), and the FY2025 full-year result was $146475.0, up 16.2% from the prior year.
• Current Deferred Revenue for Q4 2025 stood at $146475.0, up from $126056.0 in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $285221.0 in Q4 2023 and bottomed at $2820.7 in Q2 2022.
• The 5-year median for Current Deferred Revenue is $136265.5 (2024), against an average of $145225.6.
• The widest annual swing landed in 2022, when Current Deferred Revenue sank 98.82%; it then soared 296.22% in 2023.
• A 5-year view of Current Deferred Revenue shows it stood at $238795.6 in 2021, then tumbled by 69.85% to $71985.0 in 2022, then jumped by 296.22% to $285221.0 in 2023, then tumbled by 55.8% to $126056.0 in 2024, then gained by 16.2% to $146475.0 in 2025.
• The last three Current Deferred Revenue figures came in at $146475.0 (Q4 2025), $126056.0 (Q4 2024), and $285221.0 (Q4 2023), per Business Quant data.

Peer Comparison